MONOVISC is indicated for the treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e.g.

Represents the first approval in North America for its Single-Injection Osteoarthritis Treatment BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 20, 2009-- Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in ...

Anika (ANIK) won FDA approval for Monovisc, but sales will have to be strong to justify its recent move higher. Anika (NASDAQ: ANIK) jumped by a third following the FDA's approval of Monovisc, its ...

Anika Therapeutics announced that it has received FDA marketing approval for Monovisc (sodium hyaluronate [NaHA] in phosphate buffered saline), a single injection viscosupplement used to treat pain ...

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that ...

A single injection treatment for pain due to Osteoarthritis of the knee, Monovisc is the first FDA-approved single injection product with HA from a non-animal source. NASDAQ:ANIK halted in AH trade ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued marketing approval to Anika Therapeutics Inc. for its Monovisc, a single-injection supplement to ...

On Feb 26 shares were soaring for small-cap pharmaceuticals company Anika Therapeutics ($ANIK) on news that its single-injection treatment for osteoarthritis ...

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA”) technology, today announced ...

MONTREAL, May 16, 2024 /CNW/ - Pendopharm, a division of Pharmascience Canada ("Pendopharm"), is pleased to announce the renewal of its exclusive distribution agreement with Anika Therapeutics Inc ...